FP 0011

Drug Profile

FP 0011

Alternative Names: FP 0011-Backup; FP0011

Latest Information Update: 20 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Faust Pharmaceuticals
  • Developer Domain Therapeutics
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Glutamate-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

  • 25 Jan 2007 Clinical data added to the adverse events and drug interaction sections
  • 19 May 2005 Phase-II clinical trials in Amyotrophic lateral sclerosis in France (unspecified route)
  • 19 May 2005 Phase-II clinical trials in Parkinson's disease in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top